Applying Nonexperimental Study Approach to Analyze Historical Batch Data

Small Molecule Pharmaceutical Development, Genentech, Inc., South San Francisco, California 94080, USA.
Journal of Pharmaceutical Sciences (Impact Factor: 2.59). 05/2012; 101(5):1865-76. DOI: 10.1002/jps.23066
Source: PubMed


One common challenge in pharmaceutical product development is mapping the potential effects of a large number of variables. Conventional experimental tools such as design-of-experiment (DoE) approach demand study scales too large to be practical. In comparison, nonexperimental studies have the advantage to evaluate a large number of variables, but may suffer from the inability to define causal relationships. Given this situation, the current study sought to divide the mapping operation into two steps. The first step screens out potential significant variables and confirms the causal relationships, and the second step involves DoE studies to define the design space. This report demonstrates that nonexperiments can be effectively applied in the first step. The screening task was performed on the nonexperimental dataset consisting of data collected from historical batches manufactured as clinical testing materials. A combination of statistical analysis and technical assessment was applied in the screening. By invoking the variable selection procedure embedded in the multivariate regression analysis, the significance of variables to the responses was assessed. Potential technical mechanisms and variable confounding were then examined for the significant correlations identified. Experimental confirmation was performed to confirm the causal relationships. The last two measures were introduced to remedy the weakness of the nonexperiments in defining causal relationships. Through this effort, the relationships among a large number of variables were quantitatively evaluated and the variables of potential risks to product quality and manufacturability were identified. The results effectively directed further DoE studies to the high-risk variables. Overall, the nonexperimental analysis improve the mapping efficiency and may provide a data-driven decision-making platform to enhance quality risk assessment.

1 Follower
22 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multivariate data analysis methods such as partial least square (PLS) modeling have been increasingly applied to pharmaceutical product development. This study applied the PLS modeling to analyze a product development dataset generated from a design of experiment and historical batch data. Attention was paid in particular to the assessment of the importance of predictor variables, and subsequently the variable selection in the PLS modeling. The assessment indicated that irrelevant and collinear predictors could be extensively present in the initial PLS model. Therefore, variable selection is an important step in the optimization of the pharmaceutical product process model. The variable importance for projections (VIP) and coefficient values can be employed to rank the importance of predictors. On the basis of this ranking, the irrelevant predictors can be removed. To further reduce collinear predictors, multiple rounds of PLS modeling on different combinations of predictors may be necessary. To this end, stepwise reduction of predictors based on their VIP/coefficient ranking was introduced and was proven to be an effective approach to identify and remove redundant collinear predictors. Overall, the study demonstrated that the variable selection procedure implemented herein can effectively evaluate the importance of variables and optimize models of drug product processes. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.
    Journal of Pharmaceutical Sciences 12/2012; 101(12). DOI:10.1002/jps.23322 · 2.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The entire pharmaceutical sector is in an urgent need of both innovative technological solutions and fundamental scientific work, enabling the production of highly engineered drug products. Commercial-scale manufacturing of complex drug delivery systems (DDSs) using the existing technologies is challenging. This review covers important elements of manufacturing sciences, beginning with risk management strategies and design of experiments (DoE) techniques. Experimental techniques should, where possible, be supported by computational approaches. With that regard, state-of-art mechanistic process modeling techniques are described in detail. Implementation of materials science tools paves the way to molecular-based processing of future DDSs. A snapshot of some of the existing tools is presented. Additionally, general engineering principles are discussed covering process measurement and process control solutions. Last part of the review addresses future manufacturing solutions, covering continuous processing and, specifically, hot-melt processing and printing-based technologies. Finally, challenges related to implementing these technologies as a part of future health care systems are discussed. © 2015 The Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci. © 2015 The Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association.
    Journal of Pharmaceutical Sciences 08/2015; 104(11). DOI:10.1002/jps.24594 · 2.59 Impact Factor